Editorial overview: Anti-infectives 2019 volume
Section snippets
A novel view to the world of anti-infectives
Since their introduction to therapy, anti-infectives have been the primary option for treating bacterial, fungal, parasitic, and viral infections and have saved millions of lives. As a consequence, life expectancy increased, at the same time that deaths caused by biological pathogens decreased. These compounds are of crucial importance to the human being and their exploitation greatly supported the economy of the pharmaceutical industry for many years.
Besides human therapy, great amounts of
Sergio Sánchez is a professor of industrial microbiology at the University of Mexico (UNAM). His research focuses on the biochemical and molecular biology basis of secondary metabolites production and genome mining of plant-associated microbes as source of biologically active compounds. Associate Editor of a couple of international journals, cofounded the Mexican Society for Biotechnology and Bioengineering, that established the ‘Sergio Sanchez’ award to recognize the best research projects for
References (23)
- et al.
Bacterial cross-resistance to anti-infective compounds. Is it a real problem?
Curr Opin Pharmacol
(2019) - et al.
The race between drug introduction and appearance of microbial resistance. Current balance and alternative approaches
Curr Opin Pharmacol
(2019) A crucial list of pathogens
Lancet Infect Dis
(2018)Recently developed synthetic compounds with anti-infective activity
Curr Opin Pharmacol
(2019)- et al.
Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance
Curr Opin Pharmacol
(2019) - et al.
Recent findings of molecules with anti-infective activity: screening of non-conventional sources
Curr Opin Pharmacol
(2019) - et al.
Impact of ∼omics in the detection and validation of potential anti-infective drugs
Curr Opin Pharmacol
(2019) - et al.
Harnessing microbiota interactions to produce bioactive metabolites: communication signals and receptor proteins
Curr Opin Pharmacol
(2019) - et al.
Strategies for discovery of new molecular targets for anti-infective drugs
Curr Opin Pharmacol
(2019) - et al.
Antibacterials in the pipeline and perspectives for the near future
Curr Opin Pharmacol
(2019)
Barriers on the road to new antibiotics
The Scientist
Cited by (0)
Sergio Sánchez is a professor of industrial microbiology at the University of Mexico (UNAM). His research focuses on the biochemical and molecular biology basis of secondary metabolites production and genome mining of plant-associated microbes as source of biologically active compounds. Associate Editor of a couple of international journals, cofounded the Mexican Society for Biotechnology and Bioengineering, that established the ‘Sergio Sanchez’ award to recognize the best research projects for pre-postgraduate students in theses disciplines. Member of the Society for Industrial Microbiology, Mexican Academy of Sciences, and American Academy for Microbiology.
Arnold L Demain is a Research fellow in microbial biochemistry at the Charles A. Dana Research Institute for Scientists Emeriti of Drew University in Madison New Jersey. He is one of the world’s leading industrial microbiologists constantly present in the forefront of industrial microbiology and biotechnology. In recognition to his outstanding contributions, he had been awarding honorary doctorates from the University of León (Spain), Ghent University (Belgium), Technion University (Israel), Michigan State University (USA), and Muenster University (Germany).